101971-26-0

Basic information

• Product Name: 5-(4-methylphenyl)pentane-1-ol
• Synonyms: 5-(4-methylphenyl)pentane-1-ol
• CAS NO: 101971-26-0
• Molecular Weight: 178.274
• Mol File: 101971-26-0.mol

Chemical Properties

• CAS DataBase Reference: 5-(4-methylphenyl)pentane-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-methylphenyl)pentane-1-ol(101971-26-0)
• EPA Substance Registry System: 5-(4-methylphenyl)pentane-1-ol(101971-26-0)

Safety Data

• Hazardous Substances Data: 101971-26-0(Hazardous Substances Data)

Upstream product

• 76978-38-6 (E)-5-(4-methylphenyl)-4-penten-1-ol 
• 5631-95-8 2,3-dichlorotetrahydro-2H-pyran 
• 106-38-7 para-bromotoluene 
• 109-99-9 tetrahydrofuran 
• 104-82-5 4-Methylbenzyl chloride 
• 5390-04-5 pent-1-yn-5-ol 
• 624-31-7 4-tolyl iodide 
• 154477-02-8 5-(4-methylphenyl)-4-pentyne-1-ol 

Downstream Products

• 105474-18-8 5-Brom-1-p-tolyl-pentan 
• 109806-77-1 1-p-Tolyl-5-(4-nitro-2-methoxy-phenoxy)-pentan 
• 15382-79-3 1-p-Tolyl-5-<4-amino-2-methoxy-phenoxy>-pentan 

Relevant articles and documents

Ring-opening of cyclic ethers with carbon-carbon bond formation by Grignard reagents

The ring-opening of cyclic ethers with concomitant C-C bond formation was studied with a number of Grignard reagents. The transformation was performed in a sealed vial by heating to ～160 °C in an aluminum block or at 180 °C in a microwave oven. Good yields of the product alcohols were obtained with allyl- and benzylmagnesium halides when the ether was tetrahydrofuran or 3,3-dimethyloxetane. Lower yields were obtained with substituted tetrahydrofurans while no ring-opening was observed with tetrahydropyran. Only highly reactive allyl and benzyl Grignard reagents participated in the transformation while no reaction occurred with other alkylmagnesium halides.

NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE

PROBLEM TO BE SOLVED: To provide a compound that specifically activates an LPA4 receptor, and a pharmaceutical composition containing the same. SOLUTION: This invention relates to a novel lysophosphatidic acid derivative that has an agonistic action on an LPA4 receptor and is useful for the prevention and/or treatment of a disease with angiodysplasia caused by the LPA4 receptor, or a disease associated with angiopathy, or symptoms associated therewith. This invention also relates to a pharmaceutical composition containing the lysophosphatidic acid derivative. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT